BACKGROUND: Cochlear implant users with residual hearing often benefit greatly from simultaneous electric and acoustic stimulation. However, implantation can cause trauma to the inner ear, resulting in poorer hearing postoperatively. We investigated whether a single local injection of glucocorticoids can reduce hearing loss in long-term implanted guinea pigs. METHODS: Three groups of animals underwent bilateral surgery. One ear was implanted with an electrode, and the contralateral ear received a cochleostomy only. A single dose of the glucocorticoids triamcinolone or dexamethasone, or of artificial perilymph was infused into cochleae via cochleostomy. Compound action potentials were measured before and after application and for 3 months postoperatively. Tissue growth was measured as the percentage of the total area of the scala tympani that was obliterated. RESULTS: Ears subjected to cochleostomy only and treated with glucocorticoids demonstrated a mild hearing loss. In the implanted ears, both glucocorticoids preserved hearing at least temporarily. The volume of tissue growth within the scala tympani was not reduced, and there was no relation between the amount of tissue and hearing loss. CONCLUSIONS: Both glucocorticoids show a potential benefit for hearing preservation in implanted ears. Glucocorticoid therapy may be useful to protect residual hearing during cochlear implantation.
BACKGROUND: Cochlear implant users with residual hearing often benefit greatly from simultaneous electric and acoustic stimulation. However, implantation can cause trauma to the inner ear, resulting in poorer hearing postoperatively. We investigated whether a single local injection of glucocorticoids can reduce hearing loss in long-term implanted guinea pigs. METHODS: Three groups of animals underwent bilateral surgery. One ear was implanted with an electrode, and the contralateral ear received a cochleostomy only. A single dose of the glucocorticoids triamcinolone or dexamethasone, or of artificial perilymph was infused into cochleae via cochleostomy. Compound action potentials were measured before and after application and for 3 months postoperatively. Tissue growth was measured as the percentage of the total area of the scala tympani that was obliterated. RESULTS: Ears subjected to cochleostomy only and treated with glucocorticoids demonstrated a mild hearing loss. In the implanted ears, both glucocorticoids preserved hearing at least temporarily. The volume of tissue growth within the scala tympani was not reduced, and there was no relation between the amount of tissue and hearing loss. CONCLUSIONS: Both glucocorticoids show a potential benefit for hearing preservation in implanted ears. Glucocorticoid therapy may be useful to protect residual hearing during cochlear implantation.
Authors: Ya Liu; Claude Jolly; Susanne Braun; Thomas Stark; Elias Scherer; Stefan K Plontke; Jan Kiefer Journal: Eur Arch Otorhinolaryngol Date: 2015-08-29 Impact factor: 2.503
Authors: Anne Bohl; Henning W Rohm; Piera Ceschi; Gerrit Paasche; Anne Hahn; Stephan Barcikowski; Thomas Lenarz; Timo Stöver; Hans-Wilhelm Pau; Klaus-Peter Schmitz; Katrin Sternberg Journal: J Mater Sci Mater Med Date: 2012-06-17 Impact factor: 3.896
Authors: Clemens Honeder; Lukas David Landegger; Elisabeth Engleder; Franz Gabor; Roberto Plasenzotti; Hanns Plenk; Alexandra Kaider; Lena Hirtler; Wolfgang Gstoettner; Christoph Arnoldner Journal: Acta Otolaryngol Date: 2015-02-26 Impact factor: 1.494
Authors: Mareike Hütten; Anandhan Dhanasingh; Roland Hessler; Timo Stöver; Karl-Heinz Esser; Martin Möller; Thomas Lenarz; Claude Jolly; Jürgen Groll; Verena Scheper Journal: PLoS One Date: 2014-08-08 Impact factor: 3.240
Authors: Maciej Wilk; Roland Hessler; Kenneth Mugridge; Claude Jolly; Michael Fehr; Thomas Lenarz; Verena Scheper Journal: PLoS One Date: 2016-02-03 Impact factor: 3.240